Hematologic Malignancy
Malignant Mastocytosis
CI-CAN-00000239Explore in graph →
Hematologic3 active trials2 approved drugs
- NCIt
- C8991
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000239Explore in graph →
Clinical trials
14 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05362773 | A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | active not recruiting | Phase 1 | 130 | MacroGenicsINDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT06327685 | Avapritinib With Decitabine in Patients With SM-AHN | recruiting | Phase 1 | 34 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05609942 |
| Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies(AZURE) |
| terminated |
| Phase 1 |
| 9 |
| Blueprint Medicines CorporationINDUSTRY |
| 7 |
| Apr 10, 2025 |
| clinicaltrials |
| NCT02571036 | A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies | completed | Phase 1 | 282 | Deciphera Pharmaceuticals, LLCINDUSTRY | 6 | Dec 13, 2023 | clinicaltrials |
| NCT02561988 | (EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies | completed | Phase 1 | 86 | Blueprint Medicines CorporationINDUSTRY | 2 | Mar 17, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Jul 28, 2026source: clinicaltrials